KOSDAQBiotech & Pharma464490

QuadMedicine

₩3,760▼ 3.71%2026-11-18 close
Market Cap
₩43.3B
Turnover
₩70,876,375
Volume
20K
Shares out.
11.5M
PER
—
PBR
—
EPS
—
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q1–2025Q4) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Lumpy Revenue and Ongoing Losses: Pipeline Milestones Ahead

QuadMedicine relies on microneedle technology fees and partnerships for revenue, but with three straight loss-making quarters through the third quarter of 2026, the timing of a profit turn and pipeline progress remain the key checkpoints.

  1. 1

    Revenue reached KRW 10.7 billion in 2025, up 15.0% year on year, while the operating loss widened to KRW 6.38 billion.

  2. 2

    Third-quarter 2026 revenue fell 98.4% from the prior quarter to KRW 25 million, and the operating loss of KRW 3.68 billion extended a run of three straight loss-making quarters.

  3. 3

    The company has described technology-fee income as a core revenue pillar, and first-half 2025 revenue came entirely from two customers.

  4. 4

    The osteoporosis patch completed a Phase 1 trial in Australia, and an application for domestic Phase 1 trial approval was filed in October 2026.

  5. 5

    The company has targeted a return to profitability in 2027, a outlook that has not yet been confirmed by reported results.

02

Business structure

QuadMedicine develops microneedle array patch (MAP) platforms that deliver drugs through the skin. The company holds three platforms, S-MAP (separable), C-MAP (coated) and P-MAP (particle-attached), and states they can be applied to vaccines, peptides and synthetic drugs.

Its revenue base consists of technology fees and milestones from joint development and CDO contracts, with royalties added after commercialization. Once programs enter clinical stages, manufacturing equipment supply generates sales, and the company has said this equipment revenue would become meaningful from 2027.

The pipeline spans eight indications, including osteoporosis, obesity, alopecia, hepatitis B, measles-rubella, shigella and typhoid, COVID-19 and acute allergy.

Technology transfers include an osteoporosis MAP to Hanlim Pharm and obesity and acute-allergy MAPs to Sangmyung Innovation, while a vaccine MAP is in preclinical joint development with GSK.

A hepatitis B vaccine patch is in a Phase 1 trial in Korea with LG Chem, and the osteoporosis patch has completed a Phase 1 trial in Australia. At the October 2026 AAPS meeting the company presented R-MAP, a rolling-type platform, and in November 2026 it unveiled MELTRYX, a cosmetic ingredient platform.

Customer concentration is high: according to the pre-listing filing, all revenue in the first half of 2025 came from two customers. Microneedle peer Lapas is often cited domestically, but the peer group the company selected at listing consisted mainly of Korean pharmaceutical companies.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3———
2025Q4———
2026Q1₩300M-₩4.4B−1612.5%
2026Q2₩1.5B-₩2.4B−155.4%
2026Q3₩25,000,000-₩3.7B−14736.1%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2023₩1B-₩9.5B-₩9.8B−940.9%−108.9%181.4%
2024₩9.3B-₩4.4B-₩5B−47.8%−42.9%176.7%
2025₩10.7B-₩6.4B-₩6.9B−59.7%−22.3%66.2%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-18

04

Earnings analysis

According to regulatory filings, annual revenue rose from KRW 1.01 billion in 2023 to KRW 9.3 billion in 2024 (up 819.6% year on year) and reached KRW 10.7 billion in 2025 (up 15.0% year on year). Revenue increased for two consecutive years from 2024 to 2025, and 2025 was the largest year of the 2023–2025 period.

Over the same period, the operating loss was KRW 9.52 billion in 2023, KRW 4.45 billion in 2024 and KRW 6.38 billion in 2025, meaning the company posted operating losses for three straight years from 2023 to 2025.

The loss narrowed in 2024 and widened again in 2025, and the operating margin was -940.9% in 2023, -47.8% in 2024 and -59.7% in 2025. The company cited two factors behind the weaker 2025 results: listing fees, a one-off cost of the listing process, and higher personnel expenses from newly hired R&D staff.

Net loss attributable to controlling shareholders was KRW 9.76 billion in 2023, KRW 4.97 billion in 2024 and KRW 6.87 billion in 2025, and the net loss including non-controlling interests was KRW 6.93 billion in 2025.

The debt-to-equity ratio fell from 181.4% in 2023 and 176.7% in 2024 to 66.2% in 2025, largely because total equity increased to KRW 30.8 billion at the end of 2025. Operating cash flow swung from positive KRW 1.76 billion in 2023 and KRW 1.07 billion in 2024 to negative KRW 4.55 billion in 2025.

On a quarterly basis, the filed results contain no data for the third and fourth quarters of 2025, and the figures for 2026 vary widely: revenue was KRW 270 million in Q1, KRW 1.53 billion in Q2 (up 457.0% quarter on quarter) and KRW 25 million in Q3 (down 98.4% quarter on quarter).

The operating loss narrowed from KRW 4.42 billion in Q1 2026 to KRW 2.37 billion in Q2, then widened again to KRW 3.68 billion in Q3, and the net loss attributable to controlling shareholders was KRW 3.86 billion in Q3.

The combined net loss attributable to controlling shareholders over the most recent four quarters (Q1 2025 to Q4 2025) is KRW 6.87 billion.

Because quarterly revenue moves with the timing of recognition of technology fees and milestone payments, the pattern in which revenue concentrated in Q2 almost disappeared in Q3 can be read as a sign that the company's base of recurring revenue is still weak.

05

Industry analysis

Microneedles are discussed as a next-generation drug delivery technology that could displace injections, but commercial precedents remain rare. In a February 2026 report, Kiwoom Securities pointed to room-temperature distribution, cost savings and dosing precision compared with injectables as strengths.

The same report noted that manufacturing difficulty and quality control had made commercialization hard in this field. It credited the company with in-house capabilities across formulation, design and aseptic production. A 2025 article flagged institutional uncertainty and competitive dynamics as risks.

In vaccines, GSK is among the top four vaccine makers, and Kiwoom expected progress in overseas clinical trials and contracts with GSK during 2026. Domestically, Lapas is a frequently cited microneedle company but was excluded from the company's listing peer group.

Lead underwriter NH Investment & Securities said few companies with microneedle platforms have concluded as many technology-transfer deals. In cosmetics, the company plans to supply ingredients rather than sell its own brand. Its market position will likely depend on the pace of clinical progress and the number of technology transfers.

06

Outlook

The company has targeted a return to profitability in 2027. At a briefing in December 2025, it said it expected a 2027 turn to profit, citing milestones tied to its osteoporosis S-MAP contract. At the same briefing it said royalty income could be added once osteoporosis drug sales begin around 2029.

An application for domestic Phase 1 trial approval of the osteoporosis patch (PTH-MAP) was filed on October 29, 2026, which is an application rather than an approval.

The planned domestic comparative study uses a once-weekly teriparatide injection as the reference and targets 36 adult women, assessing bioavailability and safety. The company and its partners plan to combine domestic comparative data with Australian clinical data to decide on a Phase 2 or Phase 3 strategy.

A Phase 1 trial of a shigella vaccine was scheduled to start in 2027, according to a 2025 report. On manufacturing, the company plans to complete a GMP line in 2026 and build a global-supply facility in 2027 with a plan to bid in international procurement tenders.

In cosmetics, it has projected higher revenue in 2027 based on ODM supply talks. Items to watch are whether GSK-related overseas trials or contracts materialize by the end of 2026, and whether domestic Phase 1 approval for the osteoporosis patch is granted.

07

Valuation

PER
—
PBR
—
ROE
-22.3%
EPS
—
BPS
—
Dividend per share
₩0

Because the company has posted net losses over the last four quarters, its price-to-earnings ratio cannot be calculated. Dividend payouts are effectively negligible, so dividends do little to explain the share price.

Market capitalization exceeds total equity, and the gap reflects market expectations for technology-fee revenue and pipeline value. In a February 2026 report, Kiwoom Securities said that, after the listing, supply-and-demand factors had placed the share price in a phase of undervaluation.

That report's view assumes possible operating profit in 2027, so the premise depends on when earnings turn positive. The valuation at listing applied an average pharmaceutical-peer PER to estimated 2027 net income. Comparisons with historical trading ranges carry limited meaning while losses continue.

Because the company has a longer loss record than listed peers, multiple comparisons cannot be applied directly, and post-turnaround earnings levels will become the starting point for interpreting multiples.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-18

08

Bull factors

Expanding Technology Transfers and Partnerships

According to its 2025 filing, QuadMedicine has concluded three technology-transfer deals and six technology-partnership agreements. Counterparties include global pharmaceutical companies such as GSK, as well as Korean drugmakers.

In a February 2026 report, Kiwoom Securities cited commercialization progress with global pharmaceutical companies as evidence of technology competitiveness. The same report expected overseas clinical and contract progress with GSK during 2026.

Osteoporosis Patch and Pipeline Progress

The osteoporosis MAP completed a Phase 1 trial in Australia, and in October 2026 the company filed for domestic Phase 1 trial approval for PTH-MAP. Because this is an application, no approval decision has been made yet. The planned domestic comparative study would add bioavailability and safety data. The pipeline spans eight indications, and a hepatitis B vaccine is in a domestic Phase 1 trial with LG Chem.

Platform Expansion and Equipment Revenue Plans

The company presented R-MAP at the October 2026 AAPS meeting and unveiled MELTRYX at in-cosmetics Asia 2026 in November 2026, extending its skin-delivery platform into medicines and cosmetics.

It plans to build a global-supply facility in 2027 with GMP manufacturing capacity and to bid in international procurement tenders. If manufacturing-equipment sales begin, revenue sources could diversify beyond technology fees.

09

Bear factors

Persistent Operating Losses and Volatile Quarterly Sales

Operating losses have continued for three straight years from 2023 through 2025, and the operating margin was -59.7% in 2025.

Operating losses persisted for three consecutive quarters from the first quarter through the third quarter of 2026, and the third-quarter loss of KRW 3.68 billion was larger than the second-quarter loss of KRW 2.37 billion.

Third-quarter 2026 revenue was KRW 25 million, down 98.4% from the prior quarter, which points to high quarterly volatility.

Customer Concentration and Uneven Revenue Recognition

Pre-listing materials indicated that all first-half 2025 revenue came from two customers. Reports also stated that more than 90% of 2024 revenue was concentrated in those two customers, referred to as Company A and Company B.

A delay in one partner's contract progress could push back technology-fee and milestone recognition at the same time, which makes concentration a weak point.

Clinical Timelines and Supply Overhang

The osteoporosis patch's next phase depends on domestic comparative-study design and regulatory discussions before any Phase 2 or Phase 3 decision. The share of tradable shares rising about one month after listing was flagged as an overhang concern during the IPO process. Operating cash flow turned negative at KRW -4.55 billion in 2025, which leaves room for future fundraising.

10

Risk factors

Clinical and Regulatory

Most pipeline programs are in Phase 1 or preclinical stages, so commercialization requires clinical data and regulatory approval. The next step for the osteoporosis patch depends on regulatory consultation, and vaccine timing depends on the pace of the GSK collaboration. A clinical delay could also postpone technology-fee and milestone recognition.

Customer Concentration and Revenue Volatility

Revenue depends on a few customers, so changes in one partner's contract flow directly into reported results. Quarterly revenue fell from KRW 1.52 billion in the second quarter of 2026 to KRW 25 million in the third quarter.

Until equipment and cosmetics sales scale up, results may fluctuate with the timing of technology-fee recognition.

Cash Flow and Share Supply

Operating cash flow turned negative at KRW -4.55 billion in 2025. Operating losses keep working-capital needs elevated, so how the IPO proceeds are deployed is a key item to track. The period when tradable shares increase after listing has been flagged as a supply burden.

11

What to watch next

  1. Around December 2026

    Whether MFDS approves the domestic Phase 1 trial plan for the osteoporosis patch (PTH-MAP). Approval would define the design and timing of the domestic comparative study.

  2. By end-2026

    Whether overseas clinical entry or a contract announcement for the GSK vaccine MAP program occurs. Kiwoom expected progress during 2026, so the absence of news would be a factor for revising expectations.

  3. End of March 2027

    Filing of the 2026 annual report. It will confirm fourth-quarter 2026 results, full-year operating results and revenue mix, providing a baseline against the 2027 profitability target.

  4. Around mid-May 2027

    The first-quarter 2027 quarterly report. It is the first checkpoint for whether quarterly operating results show signs of turning positive.

  5. During 2027

    The start of the shigella vaccine Phase 1 trial and progress at the planned Yongin GMP facility. These are prerequisites for recognizing manufacturing-equipment revenue and expanding the pipeline.

12

Overall view

QuadMedicine's revenue model rests on technology transfers and partnerships built on its microneedle platforms. On the disclosed basis, operating losses continued from 2023 through 2025, and the operating margin worsened to -59.7% in 2025.

Operating losses have persisted for three straight quarters from the first quarter through the third quarter of 2026, and third-quarter revenue was only KRW 25 million.

Strengths include technology-transfer deals with global pharmaceutical companies, completion of the Australian Phase 1 trial and the domestic trial application for the osteoporosis patch, and platform expansion through 2026 conferences and exhibitions.

Weaknesses include customer concentration, large quarterly swings, uncertainty in clinical and regulatory timelines, and supply pressure after the listing.

In reports from late 2025 and early 2026, Kiwoom Securities and Korea Investment & Securities referred to a possible return to operating profit in 2027, but that timing depends on equipment sales and technology-fee recognition.

The next checkpoints are whether the 2026 annual report and first-quarter 2027 results show signs of a turn to profit. Domestic Phase 1 approval for the osteoporosis patch and progress with GSK are also key items for that path.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. sisajournal-e.com
  2. m.news.nate.com
  3. pharm.edaily.co.kr
  4. biospectator.com
  5. sedaily.com
  6. newstap.co.kr
  7. m.sedaily.com
  8. news.nate.com
  9. v.daum.net
  10. dailypharm.com
  11. newstap.co.kr
  12. medifonews.com
  13. etoday.co.kr
  14. thekbs.co.kr
  15. news.nate.com
  16. hankyung.com
  17. news.nate.com
  18. biotimes.co.kr

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis